Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study

Hyeon Gyu Yi; Seung-Ah Yahng; Inho Kim; Je-Hwan Lee; Chang-Ki Min; Jun Hyung Kim; Chul Soo Kim; Sun U. Song
January 2016
Korean Journal of Physiology & Pharmacology;2016, Vol. 20 Issue 1, p63
Academic Journal
Severe graft-versus-host disease (GVHD) is an often lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). The safety of clinicalgrade mesenchymal stem cells (MSCs) has been validated, but mixed results have been obtained due to heterogeneity of the MSCs. In this phase I study, the safety of bone marrow-derived homogeneous clonal MSCs (cMSCs) isolated by a new subfractionation culturing method was evaluated. cMSCs were produced in a GMP facility and intravenously administered to patients who had refractory GVHD to standard treatment resulting after allogeneic HSCT for hematologic malignancies. After administration of a single dose (1×106 cells/kg), 11 patients were evaluated for cMSC treatment safety and efficacy. During the trial, nine patients had 85 total adverse events and the rate of serious adverse events was 27.3% (3/11 patients). The only one adverse drug reaction related to cMSC administration was grade 2 myalgia in one patient. Treatment response was observed in four patients: one with acute GVHD (partial response) and three with chronic GVHD. The other chronic patients maintained stable disease during the observation period. This study demonstrates single cMSC infusion to have an acceptable safety profile and promising efficacy, suggesting that we can proceed with the next stage of the clinical trial.


Related Articles

  • Response as an end point in treatment trials for acute GVHD. Pavletic, S Z // Bone Marrow Transplantation;Feb2012, Vol. 47 Issue 2, p161 

    The author argues on that the studies have provided data that suggest day 28 as a suitable time point in measuring the response to first-line therapy in clinical trials for acute graft versus host disease (GVHD). The author stresses that the studies support the expert panel endorsement of day 28...

  • Enlivex completes enrollment for GVHD in transplant.  // Worldwide Biotech;Sep2011, Vol. 23 Issue 9, p5 

    The article reports on biotechnology firm Enlivex Therapeutics' completion of enrollment for its Phase I/II clinical trials for the treatment of graft versus host disease (GVHD) in bone marrow transplant patients in Israel. The company is expecting to recruit about 12 patients in the next three...

  • Osiris Targets GVHD With Stem Cell Therapy.  // Bioworld Week;10/22/2007, Vol. 15 Issue 43, p5 

    The article reports that Osiris Therapeutics Inc. is moving forward with a Phase III pivotal trial of its mesenchymal stem cell therapy Prochymal following the success of its Phase II trial in the U.S. The Prochymal is believed to be the first-line agent to treat acute graft-versus-host disease...

  • First-line extracorporeal photochemotherapy for acute GVHD after unmanipulated haploidentical BMT following nonmyeloablative conditioning and post transplantation CY. Castagna, L; Morabito, L; Mauro, E; Perotti, C; Bramanti, S; Sarina, B; Giordano, L; Crocchiolo, R; Santoro, A // Bone Marrow Transplantation;Feb2014, Vol. 49 Issue 2, p317 

    A letter to the editor is presented regarding the treatment of graft versus host disease using first-line extracorporeal photochemotherapy after bone marrow transplantation (BMT) in the November 11, 2013 issue.

  • Graft-versus-host disease. Denman, A.M. // British Medical Journal (Clinical Research Edition);10/30/1982, Vol. 285 Issue 6350, p1226 

    Examines the use of bone marrow transplantation in managing graft versus host diseases. Major obstacles to a successful implantation; Alternative approaches in preventing the disease; Immunosuppresive effects of graft-versus-host diseases.

  • ENZO BIOCHEM TREATMENT RIDS TRANSPLANTATION SIDE EFFECTS.  // Worldwide Biotech;Jul2000, Vol. 12 Issue 7, p1 

    Reports on the treatment developed by scientists at Hadassah University Hospital and Enzo Biochem Inc. which reversed the side effects of a graft versus host disease in an individual receiving bone marrow stem cell transplantation.

  • From Bench to Bedside: Review of Gene and Cell-Based Therapies and the Slow Advancement into Phase 3 Clinical Trials, with a Focus on Aastrom's Ixmyelocel-T. Bartel, Ronnda; Booth, Erin; Cramer, Caryn; Ledford, Kelly; Watling, Sharon; Zeigler, Frank // Stem Cell Reviews & Reports;Jun2013, Vol. 9 Issue 3, p373 

    There is a large body of preclinical research demonstrating the efficacy of gene and cellular therapy for the potential treatment of severe (limb-threatening) peripheral arterial disease (PAD), including evidence for growth and transcription factors, monocytes, and mesenchymal stem cells. While...

  • Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Kim, Nayoun; Im, Keon-Il; Lim, Jung-Yeon; Jeon, Eun-Joo; Nam, Young-Sun; Kim, Eun-Jung; Cho, Seok-Goo // Annals of Hematology;Oct2013, Vol. 92 Issue 10, p1295 

    Mesenchymal stem cells (MSCs) have emerged as a therapeutic approach in a range of medical fields, including regenerative medicine, cancer, autoimmune diseases, and inflammatory diseases, because of their unique properties of tissue repair and major histocompatibility complex-unmatched...

  • Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Teshima, Takanori; Ordemann, Rainer; Reddy, Pavan; Gagin, Svetlana; Liu, Chen; Cooke, Kenneth R.; Ferrara, James L. M. // Nature Medicine;Jun2002, Vol. 8 Issue 6, p575 

    Alloantigen expression on host antigen-presenting cells (APCs) is essential to initiate graft-versus-host disease (GvHD); therefore, alloantigen expression on host target epithelium is also thought to be essential for tissue damage. We tested this hypothesis in mouse models of GvHD using...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics